KRAS and familial pancreatic carcinoma: It is widely known that KRAS is mutated in about 90% of pancreatic cancer cases and contributes to cancer cell proliferation via the MAPK pathway and STAT3 activation; thus, many studies are now investigating ways to target STAT3 as a therapeutic intervention for KRAS-mutant pancreatic tumors [13,45].